Equities research analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to post $86.13 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for AngioDynamics’ earnings, with estimates ranging from $84.60 million to $88.78 million. AngioDynamics posted sales of $85.60 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.6%. The firm is expected to announce its next quarterly earnings report on Thursday, March 29th.

According to Zacks, analysts expect that AngioDynamics will report full-year sales of $86.13 million for the current financial year, with estimates ranging from $346.84 million to $352.27 million. For the next financial year, analysts forecast that the firm will post sales of $355.89 million per share, with estimates ranging from $350.30 million to $361.78 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for AngioDynamics.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. The firm had revenue of $86.70 million during the quarter, compared to analysts’ expectations of $88.15 million. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. AngioDynamics’s revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.19 earnings per share.

Several brokerages recently issued reports on ANGO. Zacks Investment Research raised AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Tuesday, October 3rd. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a report on Sunday, October 8th. TheStreet cut AngioDynamics from a “b-” rating to a “c” rating in a report on Tuesday, January 2nd. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a report on Friday, September 29th. Finally, BidaskClub downgraded AngioDynamics from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $18.40.

AngioDynamics (ANGO) opened at $16.35 on Tuesday. The stock has a market capitalization of $600.79, a price-to-earnings ratio of -77.85, a P/E/G ratio of 1.57 and a beta of 1.04. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85. The company has a current ratio of 2.56, a quick ratio of 1.65 and a debt-to-equity ratio of 0.17.

A number of institutional investors have recently added to or reduced their stakes in ANGO. Schwab Charles Investment Management Inc. increased its position in AngioDynamics by 44.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 339,972 shares of the medical instruments supplier’s stock worth $5,511,000 after buying an additional 105,414 shares in the last quarter. Rhumbline Advisers increased its position in AngioDynamics by 20.8% during the second quarter. Rhumbline Advisers now owns 69,970 shares of the medical instruments supplier’s stock worth $1,134,000 after buying an additional 12,038 shares in the last quarter. Bank of New York Mellon Corp increased its position in AngioDynamics by 8.9% during the second quarter. Bank of New York Mellon Corp now owns 539,410 shares of the medical instruments supplier’s stock worth $8,745,000 after buying an additional 44,311 shares in the last quarter. Legal & General Group Plc increased its position in AngioDynamics by 16.9% during the second quarter. Legal & General Group Plc now owns 61,261 shares of the medical instruments supplier’s stock worth $993,000 after buying an additional 8,860 shares in the last quarter. Finally, Comerica Bank increased its position in AngioDynamics by 2.5% during the second quarter. Comerica Bank now owns 36,068 shares of the medical instruments supplier’s stock worth $606,000 after buying an additional 893 shares in the last quarter. 95.16% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Analysts Expect AngioDynamics, Inc. (ANGO) Will Post Quarterly Sales of $86.13 Million” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/16/analysts-expect-angiodynamics-inc-ango-will-post-quarterly-sales-of-86-13-million.html.

About AngioDynamics

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get a free copy of the Zacks research report on AngioDynamics (ANGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.